Shenzhen BioX Medical Co., Ltd. stands at the forefront of the biotechnology sector as a premier manufacturer specializing in molecular diagnostic analysis systems, genetic testing solutions, and comprehensive clinical laboratory equipment. Since our establishment in 2017, we have strategically headquartered our operations in Shenzhen, China—a global nexus for high-tech medical device development and manufacturing excellence.
Our expansive manufacturing capability, spanning over 9,000 square meters, empowers our multidisciplinary team of over 200 professionals to push the boundaries of clinical biomarker solutions. We provide vital support to hospitals, research institutions, and public health organizations globally, delivering technologies that refine disease detection and genetic analysis.
Integrating AI and High-Throughput Sequencing to redefine the clinical biomarker landscape.
Moving beyond single biomarkers, our roadmap focuses on the integration of genomics, proteomics, and metabolomics into a unified diagnostic platform, allowing for 360-degree patient profiling.
Implementing machine learning algorithms into our Real-Time PCR and Genomics systems to automate pattern recognition, reducing human error in complex biomarker identification.
Development of next-generation Point-of-Care Testing (POCT) systems that deliver clinical-grade accuracy within minutes, essential for infectious disease management in remote areas.
Operating from Shenzhen gives BioX Medical an unparalleled advantage in supply chain efficiency. By leveraging the local ecosystem of high-precision component manufacturers and rapid prototyping facilities, we ensure:
Localized biomarker detection kits for early cancer screening in developed markets like Europe and North America, focusing on liquid biopsy and genetic risk factors.
Deploying rapid PCR and fluorescence analysis systems in Asia-Pacific and Africa to monitor and control outbreaks of endemic diseases with real-time data sync.
Integrating Gait Analysis and metabolic biomarkers for elite sports clinics in the Middle East and Latin America to optimize athlete recovery protocols.
The role of Clinical Biomarker Solutions has evolved from simple diagnostic confirmation to "Predictive and Preventive Medicine." At Shenzhen BioX Medical, we specialize in the engineering of high-precision instruments that detect nucleic acids, proteins, and small molecules with extreme sensitivity.
Our Nucleic Acid Testing Platforms utilize state-of-the-art thermal cycling technology to ensure uniform amplification across all channels, a critical factor for quantitative PCR (qPCR) accuracy. This precision is vital for viral load monitoring and gene expression analysis in clinical settings.
Furthermore, our Automated Laboratory Testing Systems minimize manual intervention, thereby reducing the risk of sample contamination—a major "Information Gain" for laboratories seeking to improve their operational reliability. By integrating data management capabilities, we enable hospitals to seamlessly link diagnostic results with Electronic Health Records (EHR).
The global In-Vitro Diagnostics (IVD) market is projected to grow significantly, driven by an aging population and the increasing prevalence of chronic diseases. BioX Medical contributes to this growth by providing scalable and innovative diagnostic systems. Our commitment to compliance is unwavering; we maintain comprehensive quality control procedures throughout design, manufacturing, and testing.
We serve a diverse clientele across Europe, North America, the Middle East, and Latin America, ensuring that our products meet regional regulatory requirements such as CE marking for European markets and ISO 13485 for medical device quality management systems.
Commitment to advancing modern laboratory technologies with reliable, scalable, and innovative diagnostic systems.
BioX Medical
